Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein

Xiaofeng Wu, Yukai He, Louis D. Falo, Kam M. Hui, Leaf Huang

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The tumor necrosis factor (TNF)-related apoptosis-inducing ligand, TRAIL, is a new member of the TNF family. It can specifically induce apoptosis in a variety of human tumors. To investigate the possibility of employing the TRAIL gene for systemic cancer therapy, we constructed a recombinant gene encoding the soluble form of the human Flt3L gene (hFlex) at the 5′ end and the human TRAIL gene at the 3′ end. Such design allows the TRAIL gene product to be secreted into the body circulation. We have also demonstrated that the addition of an isoleucine zipper to the N-terminal of TRAIL greatly enhanced the trimerization of the fusion protein and dramatically increased its anti-tumor activity. The fusion protein reached the level of 16-38 μg/ml in the serum after a single administration of the recombinant gene by hydrodynamic-based gene delivery in mice. A high level of the fusion protein correlated with the regression of a human breast tumor established in SCID mice. No apparent toxicity was observed in the SCID mouse model. In addition, the fusion protein caused an expansion of the dendritic cell population in the C57BL/6 recipient mice, indicating that the hFlex component of the fusion protein was functional. Thus, the hFlex-TRAIL fusion protein may provide a novel approach, with the possible involvement of dendritic cell-mediated anti-cancer immunity, for the treatment of TRAIL-sensitive tumors.

Original languageEnglish (US)
Pages (from-to)368-374
Number of pages7
JournalMolecular Therapy
Volume3
Issue number3
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Adenocarcinoma
Breast
Genes
SCID Mice
Dendritic Cells
Neoplasms
Proteins
Tumor Necrosis Factor-alpha
Protein Multimerization
Apoptosis
Isoleucine
Neoplasm Genes
Hydrodynamics
Immunity
Breast Neoplasms
Ligands
Serum
Population

Keywords

  • Cancer gene therapy
  • Flt3L (hFlex)
  • Fusion protein
  • Isoleucine zipper
  • TRAIL

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein. / Wu, Xiaofeng; He, Yukai; Falo, Louis D.; Hui, Kam M.; Huang, Leaf.

In: Molecular Therapy, Vol. 3, No. 3, 01.01.2001, p. 368-374.

Research output: Contribution to journalArticle

@article{265796b61abf48ed919d4ad6332f0dd5,
title = "Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein",
abstract = "The tumor necrosis factor (TNF)-related apoptosis-inducing ligand, TRAIL, is a new member of the TNF family. It can specifically induce apoptosis in a variety of human tumors. To investigate the possibility of employing the TRAIL gene for systemic cancer therapy, we constructed a recombinant gene encoding the soluble form of the human Flt3L gene (hFlex) at the 5′ end and the human TRAIL gene at the 3′ end. Such design allows the TRAIL gene product to be secreted into the body circulation. We have also demonstrated that the addition of an isoleucine zipper to the N-terminal of TRAIL greatly enhanced the trimerization of the fusion protein and dramatically increased its anti-tumor activity. The fusion protein reached the level of 16-38 μg/ml in the serum after a single administration of the recombinant gene by hydrodynamic-based gene delivery in mice. A high level of the fusion protein correlated with the regression of a human breast tumor established in SCID mice. No apparent toxicity was observed in the SCID mouse model. In addition, the fusion protein caused an expansion of the dendritic cell population in the C57BL/6 recipient mice, indicating that the hFlex component of the fusion protein was functional. Thus, the hFlex-TRAIL fusion protein may provide a novel approach, with the possible involvement of dendritic cell-mediated anti-cancer immunity, for the treatment of TRAIL-sensitive tumors.",
keywords = "Cancer gene therapy, Flt3L (hFlex), Fusion protein, Isoleucine zipper, TRAIL",
author = "Xiaofeng Wu and Yukai He and Falo, {Louis D.} and Hui, {Kam M.} and Leaf Huang",
year = "2001",
month = "1",
day = "1",
doi = "10.1006/mthe.2001.0280",
language = "English (US)",
volume = "3",
pages = "368--374",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein

AU - Wu, Xiaofeng

AU - He, Yukai

AU - Falo, Louis D.

AU - Hui, Kam M.

AU - Huang, Leaf

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The tumor necrosis factor (TNF)-related apoptosis-inducing ligand, TRAIL, is a new member of the TNF family. It can specifically induce apoptosis in a variety of human tumors. To investigate the possibility of employing the TRAIL gene for systemic cancer therapy, we constructed a recombinant gene encoding the soluble form of the human Flt3L gene (hFlex) at the 5′ end and the human TRAIL gene at the 3′ end. Such design allows the TRAIL gene product to be secreted into the body circulation. We have also demonstrated that the addition of an isoleucine zipper to the N-terminal of TRAIL greatly enhanced the trimerization of the fusion protein and dramatically increased its anti-tumor activity. The fusion protein reached the level of 16-38 μg/ml in the serum after a single administration of the recombinant gene by hydrodynamic-based gene delivery in mice. A high level of the fusion protein correlated with the regression of a human breast tumor established in SCID mice. No apparent toxicity was observed in the SCID mouse model. In addition, the fusion protein caused an expansion of the dendritic cell population in the C57BL/6 recipient mice, indicating that the hFlex component of the fusion protein was functional. Thus, the hFlex-TRAIL fusion protein may provide a novel approach, with the possible involvement of dendritic cell-mediated anti-cancer immunity, for the treatment of TRAIL-sensitive tumors.

AB - The tumor necrosis factor (TNF)-related apoptosis-inducing ligand, TRAIL, is a new member of the TNF family. It can specifically induce apoptosis in a variety of human tumors. To investigate the possibility of employing the TRAIL gene for systemic cancer therapy, we constructed a recombinant gene encoding the soluble form of the human Flt3L gene (hFlex) at the 5′ end and the human TRAIL gene at the 3′ end. Such design allows the TRAIL gene product to be secreted into the body circulation. We have also demonstrated that the addition of an isoleucine zipper to the N-terminal of TRAIL greatly enhanced the trimerization of the fusion protein and dramatically increased its anti-tumor activity. The fusion protein reached the level of 16-38 μg/ml in the serum after a single administration of the recombinant gene by hydrodynamic-based gene delivery in mice. A high level of the fusion protein correlated with the regression of a human breast tumor established in SCID mice. No apparent toxicity was observed in the SCID mouse model. In addition, the fusion protein caused an expansion of the dendritic cell population in the C57BL/6 recipient mice, indicating that the hFlex component of the fusion protein was functional. Thus, the hFlex-TRAIL fusion protein may provide a novel approach, with the possible involvement of dendritic cell-mediated anti-cancer immunity, for the treatment of TRAIL-sensitive tumors.

KW - Cancer gene therapy

KW - Flt3L (hFlex)

KW - Fusion protein

KW - Isoleucine zipper

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=0034993865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034993865&partnerID=8YFLogxK

U2 - 10.1006/mthe.2001.0280

DO - 10.1006/mthe.2001.0280

M3 - Article

C2 - 11273779

AN - SCOPUS:0034993865

VL - 3

SP - 368

EP - 374

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -